Estonian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
dyslipidemias/rasvumus
Link salvestatakse lõikelauale
Leht 1 alates 341 tulemused
Composition containing cinchonine as an active ingredient for preventing and treating obesity, dyslipidemia, fatty liver, or insulin resistance syndrome
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is the U.S. national stage filing under 35 U.S.C. .sctn.371 of international application PCT/KR2010/008944, filed Dec. 14, 2010, which claims benefit of Korean Patent Application No. 10-2010-0004901, filed Jan. 19, 2010.
FIELD OF THE
Composition for preventing or treating obesity, dyslipidemia, fatty liver or diabetes containing indole-3-carbinol derivative as active ingredient
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is the U.S. national stage filing under 35 U.S.C. .sctn.371 of PCT International Application PCT/KR2011/010161, filed Dec. 27, 2011, which claims priority from Korean Patent Application 10-2011-0010585, filed Feb. 7, 2011.
TECHNICAL FIELD
The
Method for treatment of obesity, dyslipidemia, fatty liver or insulin resistance syndrome comprising camphene as active ingredient
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is the U.S. national stage filing under 35 U.S.C. .sctn.371 of international application PCT/KR2009/007905, filed Dec. 29, 2009, which claims benefit of Korean Patent Application 10-2009-0022937, filed Mar. 18, 2009.
TECHNICAL FIELD
The
Implantable electroacupuncture system and method for treating dyslipidemia and obesity
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND INFORMATION
An estimated 1.1 billion adults worldwide are overweight or obese, one hundred thirty million of whom are adults in the United States. See, Haslam, D., Sattar, N., & Lean, M. (2006). Obesity--time to wake up. Bmj, 333(7569), 640-642; Flegal, K. M., Carroll, M. D., Ogden,
Pyrrolidinone derivatives as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
The present invention relates to pyrrolidinone derivatives of the formula I
##STR00001##
in which R.sup.1a, R.sup.1b, R.sup.1c, R.sup.2a, R.sup.2b, R.sup.2c, X, Y.sup.1 and Y.sup.2 are defined as indicated below. The pyrrolidinone derivatives I are GPR119 modulators and useful for the prevention
Azetidine compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
CROSS REFERENCE TO RELATED APPLICATIONS
This application claims priority benefit to EP Application No. 17305189.7, filed Feb. 21, 2017, the disclosure of which is herein incorporated by reference in its entirety.
DETAILED DESCRIPTION
The present disclosure relates to compounds of formula
Isoindolinone compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
The present invention relates to isoindolinone compounds of the formula I
##STR00001## in which A, X, R1b, R1c, R2a, R2b, R2c, R3, R4, R30, Y and Z are defined as indicated below. The isoindolinone compounds I are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity,
Implantable electroacupuncture system and method for treating dyslipidemia and obesity
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND INFORMATION
An estimated 1.1 billion adults worldwide are overweight or obese, one hundred thirty million of whom are adults in the United States. See, Haslam, D., Sattar, N., & Lean, M. (2006). Obesity--time to wake up. Bmj, 333(7569) 640-642; Flegal, K. M., Carroll, M. D., Ogden, C.
Substituted indanone compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
CROSS REFERENCE TO RELATED APPLICATIONS
This application is National Phase application under 35 U.S.C. .sctn. 371 of International Application No. PCT/EP2015/057413, filed Apr. 2, 2015, which claims priority benefit to European Application No. 14305491.4, filed Apr. 4, 2014, the disclosures of each
Substituted fused heterocycles as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
The present invention relates to heterocyclic compounds of the formula I
##STR00001## in which R1a, R1b, R1c, R2a, R2b, R2c, R3, R4, R30, A, B, E, G, Y and Z are defined as indicated below. The fused heterocyclic compounds I are GPR119 modulators and useful for the prevention and/or treatment of
Implantable electroacupuncture system and method for treating dyslipidemia and obesity
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND INFORMATION
An estimated 1.1 billion adults worldwide are overweight or obese, one hundred thirty million of whom are adults in the United States. See, Haslam, D., Sattar, N., & Lean, M. (2006). Obesity--time to wake up. Bmj, 333(7569) 640-642; Flegal, K. M., Carroll, M. D., Ogden, C.
Implantable electroacupuncture system and method for treating dyslipidemia and obesity
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND
An estimated 1.1 billion adults worldwide are overweight or obese, one hundred thirty million of whom are adults in the United States. See, Haslam, Sattar, N., & Lean, M. (2006). Obesity--time to wake up. Bmj, 333(7569), 640-642; Flegal, K. M., Carroll, M. D., Ogden, C. L., &
11-.beta.-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FIELD OF THE INVENTION
The instant invention is concerned with inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type I enzyme, including pharmaceutically acceptable salts and prodrugs thereof, which are useful as therapeutic compounds, particularly in the treatment of non-insulin dependent
Therapeutic or prophylactic agent for diabetes, obesity, dyslipidemia or metabolic syndrome comprising benzylamine derivative or pharmaceutically acceptable acid addition salt thereof
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
RELATED APPLICATIONS
This is a .sctn.371 of International Application No. PCT/JP2009/063632, with an international filing date of Jul. 31, 2009 (WO 2010/013798 A1, published Feb. 4, 2010), which is based on Japanese Patent Application No. 2008-198047, filed Jul. 31, 2008, the subject matter of which
11-.beta.-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FIELD OF THE INVENTION
The present invention relates to inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase Type I (11.beta.-HSD-1 or HSD-1), and methods of treatment using such compounds. The compounds are useful for the treatment of diabetes, such as non-insulin dependent type 2 diabetes
Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus
- Töötab 55 keeles
- Taimsed ravimid, mida toetab teadus
- Maitsetaimede äratundmine pildi järgi
- Interaktiivne GPS-kaart - märgistage ürdid asukohas (varsti)
- Lugege oma otsinguga seotud teaduspublikatsioone
- Otsige ravimtaimi nende mõju järgi
- Korraldage oma huvisid ja hoidke end kursis uudisteuuringute, kliiniliste uuringute ja patentidega
Sisestage sümptom või haigus ja lugege ravimtaimede kohta, mis võivad aidata, tippige ürdi ja vaadake haigusi ja sümptomeid, mille vastu seda kasutatakse.
* Kogu teave põhineb avaldatud teaduslikel uuringutel
